Amicus Therapeutics US, LLC
Philadelphia, PA Part of Amicus Therapeutics, Inc.
- UEI
- KLJFGENKMD89
- CAGE
- 867U3
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Amicus Therapeutics, Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
Amicus Therapeutics, Inc.
FJDHZ9PWMZ14
-
Parent
Amicus Therapeutics, Inc.
FJDHZ9PWMZ14
- SAM.gov registration date
- Physical address
- 3675 Market St Fl 14, Philadelphia, PA 19104, USA
- Website
- amicusrx.com
- Founded
- 2002
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $22,840 |
| FY2026 | $1,111,554 |
| FY2025 | $1,192,792 |
| FY2024 | $978,666 |
| FY2023 | $714,605 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $1,134,393 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Catalyst Pharmaceuticals, Inc. | Coral Gables, FL | 325412 Pharmaceutical Preparation Manufacturing |
| Travere Therapeutics, Inc. | San Diego, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Sanofi Genzyme | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Alexion Pharmaceuticals Inc. | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Mirum Pharmaceuticals, Inc. | San Mateo, CA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Amicus Therapeutics US, LLC, a subsidiary of biopharmaceutical company Amicus Therapeutics, Inc., supplies Galafold (migalastat) 123 mg capsules—an FDA-approved enzyme replacement therapy for Fabry disease treatment—directly to the Department of Veterans Affairs as a prime contractor under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), competing full-and-open with no set-aside designations.
Amicus Therapeutics US, LLC is a for-profit corporate entity headquartered in Philadelphia, Pennsylvania, operating under primary PSC code Drugs and Biologicals (122 awards) and NAICS Pharmaceutical Preparation Manufacturing. The vendor competes exclusively as a prime contractor on a full-and-open basis; all 122 recent federal awards are prime contracts with zero subcontract work. The company holds a single parent vehicle: a $13.0 million multiple-award Federal Supply Schedule contract (36F79724D0185) under Pharmaceuticals and Drugs (FSS-61-IB), awarded September 1, 2024, and valid through August 31, 2029. Since that award, Amicus Therapeutics US, LLC has issued 118 delivery task orders valued at $4.8 million combined potential value, with individual orders ranging from approximately $18,500 to $295,000.
Customer concentration is entirely within the Veterans Health Administration. The top five funding VISNs account for 98% of award count and 99% of combined potential value. Veterans Integrated Service Network 12 anchors 73% of combined potential value through three awards, including the $13.0 million parent FSS contract itself; VISN 5 (Mid-Atlantic region, Philadelphia area) has placed 67 delivery orders worth $1.4 million combined potential value and represents the highest-volume operational customer. VISN 9 has issued 28 orders worth $1.3 million. VISN 7 has placed 9 orders worth $1.4 million. VISN 21 has placed 9 orders worth $195 thousand. VISN 19 has placed 6 orders worth $640 thousand. No other federal agencies appear in the award portfolio.
Award activity has grown from 18 in 2022 to a peak of 31 in 2024, with 20 awards in 2025 and 15 through September 2026. Only two awards (combined potential value $523 thousand) face ultimate completion within the next twenty-four months, presenting minimal recompete cliff exposure near term. The parent FSS contract itself does not expire until August 31, 2029.
Representative delivery orders include a $22.8 thousand order from VISN 5 on September 29, 2026, for Galafold 123 mg capsules; a $68.5 thousand emergency pharmacy order from VISN 9 on August 24, 2026; a $228.4 thousand order from VISN 7 on February 23, 2026; a $295.0 thousand order from VISN 19 on November 15, 2025; and a $197.0 thousand order from VISN 7 on January 21, 2025. Delivery orders typically carry short performance windows (days to weeks), consistent with urgent pharmaceutical procurement patterns, and many are explicitly designated as emergency pharmacy purchases. All orders are firm fixed-price with no set-aside applied.
Combined potential value across all 122 awards is $18.1 million, with $4.9 million obligated (27% of potential). The vendor's footprint is narrowly specialized: Galafold supply to VA networks nationwide, with place of performance in Philadelphia, Pennsylvania or occasionally at VA facility locations. Amicus Therapeutics US, LLC performs as sole prime with no subcontractor involvement, maintaining direct control over the specialized supply chain for this rare-disease treatment critical to veteran care.
Quick answers
Is Amicus Therapeutics US, LLC registered in SAM.gov?
Yes. Amicus Therapeutics US, LLC's SAM.gov registration is active through February 6, 2027.
What is Amicus Therapeutics US, LLC's CAGE code?
Amicus Therapeutics US, LLC's CAGE code is 867U3, and its Unique Entity ID (UEI) is KLJFGENKMD89.
Which contract vehicles does Amicus Therapeutics US, LLC hold?
Amicus Therapeutics US, LLC holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Amicus Therapeutics US, LLC received in federal contracts?
Federal contracts obligated $1,192,792 to Amicus Therapeutics US, LLC in fiscal year 2025 and $4,020,456 in fiscal years 2023 through 2027.
How does Amicus Therapeutics US, LLC rank among federal contractors?
Amicus Therapeutics US, LLC's parent company, Amicus Therapeutics, Inc., ranked #71 in NAICS 325412 and #100 in PSC 6505 in FY2025.
What is Amicus Therapeutics US, LLC's most recent federal award?
Amicus Therapeutics US, LLC's most recent federal contract award is Pharmacy drug order of galafold 123MG tablets. This medication is for a patient at the perry point VA medical center (36C24527N0126), from Veterans Integrated Service Network 5 (VHA), on October 26, 2026.
On GovTribe
See Amicus Therapeutics US, LLC's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors